Leprosy Mailing List – July 13, 2018
Ref.: (LML) Manifest against the implementation of U-MDT
From: Narasimba Rao, Hyderabad, India
Dear Pieter,
We are having an absorbing discussion on the proposed implementation of U-MDT of 6 months duration for all leprosy patients in Brazil.
Today (13 July 2108), in the 'annual meeting of state leprosy officers' being held in Goa, India, Dr Ervin Cooreman, team leader global leprosy programme, in his talk titled 'brief review new WHO guidelines', spoke briefly on the new proposed guidelines for leprosy.
The important new strategy he mentioned was:
to retain the same 3 drug combination of rifampicin, dapsone and clofazimine for leprosy therapy, however all the 3 drugs to be used to all leprosy patients; for 6-month duration for PB-MDT and for 12-month duration for MB-MDT.
This is definitely very good news to global leprosy programme as the new therapy guidelines do not shorten the duration of therapy for MB cases to 6 months (as was envisaged in the U-MDT proposal).
It is only a uniform drug regimen, but of different durations for PB and MB leprosy.
It includes the drug clofazimine into the drug regimen of PB leprosy
In response to the question whether this means that U-MDT of 6 months is completely discarded, Dr Cooremen replied that he can only say that it is not being considered for now.
I just thought I shall share this Information with fellow LML readers at this juncture.
Please find as attachment the jpg of the synopsis provided to all the delegates regarding the same.
With best regards,
P Narasimha Rao
--
P. Narasimha Rao, MD, D.D, PhD
President- Elect, National IADVL 2018
Phone- 040-23514566
Mobile-09849044898
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
No comments:
Post a Comment